A vaccine combined with Keytruda is associated with a 49% reduction in the risk of recurrence or death. Among patients with advanced melanoma, long-term data have shown that a personalized mRNA cancer ...
The new structure will help Merck as it slides toward a loss of exclusivity for Keytruda, pharma’s best-selling drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results